Concepts (268)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 8 | 2024 | 32 | 3.260 |
Why?
|
| Congenital Abnormalities | 7 | 2024 | 9 | 2.460 |
Why?
|
| Vagina | 10 | 2024 | 14 | 2.290 |
Why?
|
| Uterus | 7 | 2024 | 11 | 2.190 |
Why?
|
| Humans | 58 | 2024 | 5357 | 2.020 |
Why?
|
| Laparoscopy | 6 | 2024 | 15 | 1.740 |
Why?
|
| Mullerian Ducts | 6 | 2024 | 6 | 1.670 |
Why?
|
| Cardiovascular Diseases | 4 | 2024 | 44 | 1.430 |
Why?
|
| Female | 27 | 2024 | 2752 | 1.380 |
Why?
|
| Coronary Artery Disease | 3 | 2023 | 14 | 1.280 |
Why?
|
| Urogenital Abnormalities | 4 | 2024 | 4 | 1.270 |
Why?
|
| Quality of Life | 3 | 2024 | 112 | 1.250 |
Why?
|
| Stroke Volume | 6 | 2024 | 13 | 1.220 |
Why?
|
| Myocarditis | 3 | 2022 | 3 | 1.190 |
Why?
|
| Abnormalities, Multiple | 2 | 2023 | 2 | 1.080 |
Why?
|
| Myocardial Ischemia | 2 | 2023 | 4 | 1.070 |
Why?
|
| Cardiac Rehabilitation | 1 | 2024 | 1 | 0.970 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2024 | 10 | 0.960 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2024 | 2 | 0.950 |
Why?
|
| Vaginal Neoplasms | 1 | 2023 | 1 | 0.880 |
Why?
|
| Vaginal Fistula | 1 | 2023 | 1 | 0.870 |
Why?
|
| Myocardial Infarction | 4 | 2024 | 11 | 0.840 |
Why?
|
| Surgery, Plastic | 1 | 2022 | 1 | 0.840 |
Why?
|
| Trace Elements | 1 | 2022 | 1 | 0.830 |
Why?
|
| Round Ligament of Uterus | 1 | 2022 | 1 | 0.830 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 16 | 0.810 |
Why?
|
| Neoplasms | 1 | 2023 | 98 | 0.790 |
Why?
|
| Endoscopic Mucosal Resection | 1 | 2021 | 1 | 0.750 |
Why?
|
| Leiomyoma | 1 | 2021 | 1 | 0.750 |
Why?
|
| Polyps | 1 | 2021 | 1 | 0.750 |
Why?
|
| Retrospective Studies | 13 | 2024 | 382 | 0.750 |
Why?
|
| Myocardium | 1 | 2021 | 35 | 0.740 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 37 | 0.730 |
Why?
|
| 46, XX Disorders of Sex Development | 4 | 2024 | 4 | 0.710 |
Why?
|
| Aged | 7 | 2024 | 822 | 0.650 |
Why?
|
| Pregnancy | 6 | 2024 | 103 | 0.640 |
Why?
|
| Hospitalization | 5 | 2024 | 38 | 0.620 |
Why?
|
| Male | 12 | 2024 | 2704 | 0.590 |
Why?
|
| Aortic Valve Stenosis | 3 | 2022 | 3 | 0.580 |
Why?
|
| Transcatheter Aortic Valve Replacement | 3 | 2022 | 3 | 0.580 |
Why?
|
| Defibrillators, Implantable | 3 | 2021 | 3 | 0.580 |
Why?
|
| Cardiomyopathies | 3 | 2021 | 7 | 0.580 |
Why?
|
| Telemedicine | 3 | 2023 | 35 | 0.570 |
Why?
|
| Middle Aged | 8 | 2024 | 1068 | 0.560 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2024 | 17 | 0.500 |
Why?
|
| Endometriosis | 2 | 2024 | 2 | 0.480 |
Why?
|
| Live Birth | 2 | 2024 | 2 | 0.460 |
Why?
|
| Prospective Studies | 6 | 2024 | 130 | 0.460 |
Why?
|
| Prevalence | 6 | 2024 | 68 | 0.460 |
Why?
|
| Cervix Uteri | 3 | 2022 | 7 | 0.460 |
Why?
|
| Premature Birth | 2 | 2024 | 3 | 0.440 |
Why?
|
| Hysterectomy | 2 | 2024 | 2 | 0.440 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2024 | 39 | 0.430 |
Why?
|
| Uterine Cervical Diseases | 2 | 2022 | 2 | 0.410 |
Why?
|
| Hypertension, Pulmonary | 2 | 2022 | 3 | 0.410 |
Why?
|
| Ventricular Function, Left | 4 | 2024 | 8 | 0.390 |
Why?
|
| Adult | 12 | 2024 | 1651 | 0.390 |
Why?
|
| Pacemaker, Artificial | 2 | 2021 | 4 | 0.390 |
Why?
|
| ST Elevation Myocardial Infarction | 2 | 2021 | 3 | 0.390 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2021 | 2 | 0.390 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 301 | 0.380 |
Why?
|
| Prognosis | 3 | 2023 | 59 | 0.320 |
Why?
|
| Cohort Studies | 6 | 2024 | 128 | 0.310 |
Why?
|
| Surgically-Created Structures | 2 | 2024 | 2 | 0.280 |
Why?
|
| Inflammasomes | 2 | 2024 | 39 | 0.280 |
Why?
|
| Biopsy | 2 | 2024 | 14 | 0.250 |
Why?
|
| Vitamin D Deficiency | 1 | 2024 | 3 | 0.250 |
Why?
|
| Dietary Supplements | 1 | 2024 | 8 | 0.240 |
Why?
|
| Vitamin D | 1 | 2024 | 4 | 0.240 |
Why?
|
| Walk Test | 1 | 2024 | 2 | 0.240 |
Why?
|
| Valsartan | 1 | 2024 | 1 | 0.240 |
Why?
|
| Aminobutyrates | 1 | 2024 | 5 | 0.240 |
Why?
|
| Tetrazoles | 1 | 2024 | 4 | 0.240 |
Why?
|
| Metabolome | 1 | 2024 | 6 | 0.240 |
Why?
|
| Biphenyl Compounds | 1 | 2024 | 8 | 0.240 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2024 | 4 | 0.240 |
Why?
|
| Abortion, Spontaneous | 1 | 2024 | 1 | 0.240 |
Why?
|
| Pregnancy Outcome | 1 | 2024 | 6 | 0.240 |
Why?
|
| Appendix | 1 | 2024 | 1 | 0.240 |
Why?
|
| Life Style | 1 | 2024 | 13 | 0.240 |
Why?
|
| Drug Combinations | 1 | 2024 | 25 | 0.240 |
Why?
|
| Heart Diseases | 2 | 2022 | 11 | 0.240 |
Why?
|
| Indocyanine Green | 1 | 2024 | 4 | 0.240 |
Why?
|
| Fertility | 1 | 2024 | 8 | 0.240 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2024 | 1 | 0.240 |
Why?
|
| Isoproterenol | 1 | 2024 | 3 | 0.240 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2024 | 10 | 0.230 |
Why?
|
| Postpartum Hemorrhage | 1 | 2024 | 1 | 0.230 |
Why?
|
| Adenomyosis | 1 | 2024 | 1 | 0.230 |
Why?
|
| Adolescent | 6 | 2024 | 800 | 0.230 |
Why?
|
| Fertilization | 1 | 2023 | 1 | 0.230 |
Why?
|
| United States | 2 | 2023 | 505 | 0.220 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2023 | 1 | 0.220 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 6 | 0.220 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2023 | 1 | 0.220 |
Why?
|
| Adenocarcinoma | 1 | 2023 | 10 | 0.220 |
Why?
|
| Pregnancy, Twin | 1 | 2023 | 1 | 0.220 |
Why?
|
| Twins, Monozygotic | 1 | 2023 | 2 | 0.220 |
Why?
|
| Nitric Oxide Synthase | 1 | 2023 | 2 | 0.220 |
Why?
|
| Atherosclerosis | 1 | 2023 | 16 | 0.220 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2023 | 6 | 0.220 |
Why?
|
| Adenosine Triphosphate | 1 | 2023 | 19 | 0.220 |
Why?
|
| Colitis, Ulcerative | 1 | 2023 | 1 | 0.220 |
Why?
|
| Colon, Sigmoid | 1 | 2023 | 1 | 0.220 |
Why?
|
| Menopause | 1 | 2023 | 6 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 19 | 0.210 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2022 | 1 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2023 | 51 | 0.210 |
Why?
|
| Italy | 4 | 2024 | 6 | 0.210 |
Why?
|
| Vitamin A | 1 | 2022 | 1 | 0.210 |
Why?
|
| Vitamins | 1 | 2022 | 1 | 0.210 |
Why?
|
| Ligaments | 1 | 2022 | 1 | 0.210 |
Why?
|
| Rectum | 1 | 2022 | 1 | 0.210 |
Why?
|
| Micronutrients | 1 | 2022 | 4 | 0.210 |
Why?
|
| Pelvis | 1 | 2022 | 3 | 0.210 |
Why?
|
| Antioxidants | 1 | 2022 | 24 | 0.210 |
Why?
|
| Cesarean Section | 1 | 2022 | 3 | 0.210 |
Why?
|
| Microvascular Angina | 1 | 2022 | 1 | 0.210 |
Why?
|
| Hematocolpos | 1 | 2022 | 1 | 0.200 |
Why?
|
| Hematometra | 1 | 2022 | 1 | 0.200 |
Why?
|
| Vaginal Diseases | 1 | 2022 | 3 | 0.200 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2022 | 1 | 0.200 |
Why?
|
| Vena Cava, Superior | 1 | 2022 | 1 | 0.200 |
Why?
|
| Catheter Ablation | 1 | 2022 | 1 | 0.200 |
Why?
|
| Tachycardia, Ventricular | 1 | 2022 | 1 | 0.200 |
Why?
|
| Ventricular Premature Complexes | 1 | 2022 | 1 | 0.200 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2022 | 1 | 0.200 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 2 | 0.200 |
Why?
|
| Deprescriptions | 1 | 2022 | 3 | 0.200 |
Why?
|
| Hospital Mortality | 1 | 2022 | 9 | 0.200 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 2 | 0.200 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 16 | 0.200 |
Why?
|
| Electrocardiography | 1 | 2022 | 13 | 0.200 |
Why?
|
| Exercise | 1 | 2024 | 173 | 0.200 |
Why?
|
| Oxidative Stress | 1 | 2022 | 57 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 248 | 0.200 |
Why?
|
| Sodium | 1 | 2021 | 13 | 0.190 |
Why?
|
| Atrial Fibrillation | 1 | 2021 | 15 | 0.190 |
Why?
|
| Glucose | 1 | 2021 | 13 | 0.190 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 15 | 0.190 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 13 | 0.190 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 4 | 0.190 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2021 | 1 | 0.190 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2021 | 1 | 0.190 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2021 | 20 | 0.190 |
Why?
|
| Heart Injuries | 1 | 2021 | 1 | 0.190 |
Why?
|
| Fibrosis | 1 | 2021 | 14 | 0.190 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 97 | 0.190 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2021 | 1 | 0.190 |
Why?
|
| Embolism, Paradoxical | 1 | 2021 | 1 | 0.190 |
Why?
|
| Foramen Ovale, Patent | 1 | 2021 | 1 | 0.190 |
Why?
|
| Thromboembolism | 1 | 2021 | 2 | 0.190 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 10 | 0.190 |
Why?
|
| Pediatrics | 1 | 2021 | 6 | 0.190 |
Why?
|
| Stroke | 1 | 2021 | 48 | 0.170 |
Why?
|
| Hypertension | 1 | 2021 | 61 | 0.170 |
Why?
|
| Mutation | 1 | 2021 | 135 | 0.170 |
Why?
|
| Infant, Newborn | 3 | 2024 | 49 | 0.160 |
Why?
|
| Young Adult | 4 | 2024 | 837 | 0.160 |
Why?
|
| Pandemics | 3 | 2023 | 82 | 0.150 |
Why?
|
| Risk Factors | 3 | 2023 | 183 | 0.140 |
Why?
|
| Birth Weight | 2 | 2024 | 4 | 0.110 |
Why?
|
| Coronary Angiography | 2 | 2023 | 5 | 0.110 |
Why?
|
| Coronary Vessels | 2 | 2023 | 25 | 0.100 |
Why?
|
| Epithelium | 2 | 2024 | 9 | 0.100 |
Why?
|
| Rats | 2 | 2024 | 250 | 0.100 |
Why?
|
| Hospitals | 2 | 2022 | 10 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2023 | 208 | 0.100 |
Why?
|
| Kidney | 2 | 2022 | 53 | 0.100 |
Why?
|
| Electric Impedance | 2 | 2021 | 15 | 0.100 |
Why?
|
| Heart | 2 | 2021 | 45 | 0.090 |
Why?
|
| Child | 2 | 2023 | 649 | 0.080 |
Why?
|
| Animals | 2 | 2024 | 1798 | 0.070 |
Why?
|
| Consensus | 1 | 2024 | 14 | 0.060 |
Why?
|
| Precision Medicine | 1 | 2024 | 13 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2024 | 16 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 22 | 0.060 |
Why?
|
| Urinary Bladder Diseases | 1 | 2024 | 1 | 0.060 |
Why?
|
| Cecal Diseases | 1 | 2024 | 1 | 0.060 |
Why?
|
| Ovarian Diseases | 1 | 2024 | 1 | 0.060 |
Why?
|
| Ureteral Diseases | 1 | 2024 | 1 | 0.060 |
Why?
|
| Ureter | 1 | 2024 | 2 | 0.060 |
Why?
|
| Operative Time | 1 | 2024 | 3 | 0.060 |
Why?
|
| Proof of Concept Study | 1 | 2024 | 7 | 0.060 |
Why?
|
| Myoblasts, Cardiac | 1 | 2024 | 1 | 0.060 |
Why?
|
| Cardiomegaly | 1 | 2024 | 4 | 0.060 |
Why?
|
| Somites | 1 | 2024 | 1 | 0.060 |
Why?
|
| Myocardial Contraction | 1 | 2024 | 7 | 0.060 |
Why?
|
| Cell Line | 1 | 2024 | 82 | 0.060 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2024 | 33 | 0.060 |
Why?
|
| Fertilization in Vitro | 1 | 2023 | 3 | 0.060 |
Why?
|
| Probability | 1 | 2023 | 11 | 0.060 |
Why?
|
| Cardiotonic Agents | 1 | 2023 | 1 | 0.060 |
Why?
|
| Myocytes, Cardiac | 1 | 2024 | 40 | 0.060 |
Why?
|
| Aftercare | 1 | 2023 | 6 | 0.060 |
Why?
|
| Disease Management | 1 | 2023 | 6 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2023 | 34 | 0.060 |
Why?
|
| Patient Discharge | 1 | 2023 | 17 | 0.060 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 15 | 0.050 |
Why?
|
| Diet, High-Fat | 1 | 2023 | 35 | 0.050 |
Why?
|
| Lipid Peroxides | 1 | 2022 | 1 | 0.050 |
Why?
|
| Return to Sport | 1 | 2022 | 2 | 0.050 |
Why?
|
| Europe | 1 | 2022 | 3 | 0.050 |
Why?
|
| Athletes | 1 | 2022 | 8 | 0.050 |
Why?
|
| Inflammation | 1 | 2023 | 59 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2023 | 73 | 0.050 |
Why?
|
| Embryo Transfer | 1 | 2022 | 1 | 0.050 |
Why?
|
| Pregnancy Rate | 1 | 2022 | 3 | 0.050 |
Why?
|
| Chest Pain | 1 | 2022 | 2 | 0.050 |
Why?
|
| Conservative Treatment | 1 | 2022 | 1 | 0.050 |
Why?
|
| Dysmenorrhea | 1 | 2022 | 1 | 0.050 |
Why?
|
| Abdominal Pain | 1 | 2022 | 3 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 3 | 0.050 |
Why?
|
| Anastomosis, Surgical | 1 | 2022 | 2 | 0.050 |
Why?
|
| Coronary Circulation | 1 | 2022 | 6 | 0.050 |
Why?
|
| Microcirculation | 1 | 2022 | 7 | 0.050 |
Why?
|
| Dyspnea | 1 | 2022 | 1 | 0.050 |
Why?
|
| Phenotype | 1 | 2022 | 72 | 0.050 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2022 | 1 | 0.050 |
Why?
|
| Cephalosporins | 1 | 2022 | 13 | 0.050 |
Why?
|
| Papillary Muscles | 1 | 2022 | 2 | 0.050 |
Why?
|
| Adolescent Health | 1 | 2022 | 1 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2022 | 11 | 0.050 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2022 | 3 | 0.050 |
Why?
|
| Hypoxia | 1 | 2022 | 12 | 0.050 |
Why?
|
| Ventricular Remodeling | 1 | 2021 | 2 | 0.050 |
Why?
|
| Oxygen Consumption | 1 | 2022 | 24 | 0.050 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2021 | 10 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2022 | 11 | 0.050 |
Why?
|
| Heart Ventricles | 1 | 2022 | 25 | 0.050 |
Why?
|
| Registries | 1 | 2022 | 24 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2022 | 26 | 0.050 |
Why?
|
| Ethanol | 1 | 2022 | 45 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 32 | 0.050 |
Why?
|
| Exercise Test | 1 | 2022 | 42 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2021 | 18 | 0.050 |
Why?
|
| Electronics | 1 | 2021 | 13 | 0.050 |
Why?
|
| Obesity | 1 | 2023 | 118 | 0.050 |
Why?
|
| Logistic Models | 1 | 2022 | 66 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2021 | 15 | 0.050 |
Why?
|
| Pain | 1 | 2022 | 40 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 1 | 0.050 |
Why?
|
| Syndrome | 1 | 2021 | 4 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2021 | 2 | 0.050 |
Why?
|
| Prealbumin | 1 | 2021 | 3 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2021 | 7 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2021 | 5 | 0.050 |
Why?
|
| Troponin T | 1 | 2021 | 1 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 20 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 4 | 0.050 |
Why?
|
| Cardiac Catheterization | 1 | 2021 | 3 | 0.050 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2021 | 3 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 6 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2021 | 26 | 0.050 |
Why?
|
| Echocardiography | 1 | 2021 | 10 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2022 | 102 | 0.050 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2021 | 1 | 0.050 |
Why?
|
| Blood Pressure Determination | 1 | 2021 | 2 | 0.050 |
Why?
|
| Recurrence | 1 | 2021 | 26 | 0.050 |
Why?
|
| Age Factors | 1 | 2021 | 74 | 0.050 |
Why?
|
| Lung | 1 | 2021 | 42 | 0.050 |
Why?
|
| Fluoroscopy | 1 | 2020 | 5 | 0.050 |
Why?
|
| Aortic Valve | 1 | 2020 | 4 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 275 | 0.050 |
Why?
|
| Sex Factors | 1 | 2021 | 77 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2021 | 39 | 0.050 |
Why?
|
| Biomarkers | 1 | 2021 | 85 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 166 | 0.040 |
Why?
|